CareFusion Receives Consensus Recommendation of “Buy” from Brokerages (NYSE:CFN)
Shares of CareFusion (NYSE:CFN) have been given a consensus recommendation of “Buy” by the nine analysts that are currently covering the stock, Analyst Ratings Network.com reports. Five research analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $43.44.
Shares of CareFusion (NYSE:CFN) opened at 43.73 on Friday. CareFusion has a one year low of $35.01 and a one year high of $45.81. The stock has a 50-day moving average of $44.4 and a 200-day moving average of $41.62. The company has a market cap of $9.066 billion and a price-to-earnings ratio of 24.47.
A number of research firms have recently commented on CFN. Analysts at Zacks reiterated a “neutral” rating on shares of CareFusion in a research note on Thursday, July 31st. They now have a $47.00 price target on the stock. Separately, analysts at Topeka Capital Markets initiated coverage on shares of CareFusion in a research note on Thursday, June 12th. They set a “hold” rating and a $44.00 price target on the stock. Finally, analysts at Raymond James raised their price target on shares of CareFusion from $48.00 to $50.00 in a research note on Monday, May 19th. They now have a “strong-buy” rating on the stock.
CareFusion Corporation (NYSE:CFN) is a global medical technology company.
Receive News & Ratings for CareFusion Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareFusion Co and related companies with Analyst Ratings Network's FREE daily email newsletter.